ATE288758T1 - Verfahren zur herstellung von polymorphen des clarithromycins - Google Patents

Verfahren zur herstellung von polymorphen des clarithromycins

Info

Publication number
ATE288758T1
ATE288758T1 AT00986367T AT00986367T ATE288758T1 AT E288758 T1 ATE288758 T1 AT E288758T1 AT 00986367 T AT00986367 T AT 00986367T AT 00986367 T AT00986367 T AT 00986367T AT E288758 T1 ATE288758 T1 AT E288758T1
Authority
AT
Austria
Prior art keywords
clarithromycin
polymorphoes
producing
converting
processes
Prior art date
Application number
AT00986367T
Other languages
English (en)
Inventor
Igor Lifshitz
Ilya Avrutov
Edi Schwartz
Basem Masarwa
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22640371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE288758(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE288758T1 publication Critical patent/ATE288758T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00986367T 2000-01-11 2000-12-15 Verfahren zur herstellung von polymorphen des clarithromycins ATE288758T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17547700P 2000-01-11 2000-01-11
PCT/US2000/033844 WO2001051059A1 (en) 2000-01-11 2000-12-15 Processes for preparing clarithromycin polymorphs

Publications (1)

Publication Number Publication Date
ATE288758T1 true ATE288758T1 (de) 2005-02-15

Family

ID=22640371

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00986367T ATE288758T1 (de) 2000-01-11 2000-12-15 Verfahren zur herstellung von polymorphen des clarithromycins

Country Status (22)

Country Link
US (2) US6624292B2 (de)
EP (1) EP1280535B1 (de)
JP (1) JP2003519661A (de)
KR (1) KR20020071012A (de)
CN (1) CN1450903A (de)
AT (1) ATE288758T1 (de)
AU (2) AU2261901A (de)
BR (1) BR0016992A (de)
CA (1) CA2397092A1 (de)
DE (1) DE60018119T2 (de)
DK (1) DK1280535T3 (de)
ES (1) ES2236023T3 (de)
HR (1) HRP20020572A2 (de)
HU (1) HUP0204252A3 (de)
IL (1) IL150698A0 (de)
IS (1) IS6463A (de)
PL (1) PL356645A1 (de)
PT (1) PT1280535E (de)
RU (1) RU2002118308A (de)
SI (1) SI1280535T1 (de)
WO (1) WO2001051059A1 (de)
ZA (1) ZA200205229B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1254146E (pt) * 1999-12-16 2005-10-31 Teva Pharma Processos de preparacao de polimeros de claritromicina e novo polimorfo iv
PL356645A1 (en) * 2000-01-11 2004-06-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
AU2578701A (en) * 2000-02-29 2001-09-12 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
KR20030011797A (ko) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
ES2288898T3 (es) * 2001-08-13 2008-02-01 Fondazione Salvatore Maugeri - Clinica del Lavoro e della Riabilitazione Uso de composiciones de claritromicina en la fabricacion de un medicamento para el tratamiento de la artritis deformante.
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
EP1648415A4 (de) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Antibiotisches produkt, seine verwendung und formulierung
CA2533292C (en) * 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1648418A4 (de) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc Antibiotisches produkt, seine verwendung und formulierung
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) * 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1658034A4 (de) * 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc Antibiotisches produkt, seine verwendung und formulierung
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005061524A2 (en) * 2003-12-22 2005-07-07 Ranbaxy Laboratories Limited Process for the preparation of form ii clarithromycin
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
AU2005209318B2 (en) * 2004-01-28 2010-02-11 Cytimmune Sciences, Inc. Functionalized colloidal metal compositions and methods
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US8715727B2 (en) * 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
US20070122483A1 (en) * 2005-11-29 2007-05-31 Sharon Myers Fluocinolone acetonide drug substance polymorphic interconversion
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US20120219625A1 (en) * 2009-09-02 2012-08-30 Bernard Charles Sherman Clarithromycin extended-release tablet
EP3578546A1 (de) 2013-11-15 2019-12-11 Akebia Therapeutics Inc. Feste formen von {[5-(3-chlorophenyl)-3-hydroxypyridin-2-carbonyl]amino}essigsäure, zusammensetzungen und verwendungen davon

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2473525A1 (fr) 1980-01-11 1981-07-17 Roussel Uclaf Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (ja) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4672056A (en) 1985-11-12 1987-06-09 Abbott Laboratories Erythromycin A derivatives and method of use
US4640910A (en) 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
GB8721165D0 (en) 1987-09-09 1987-10-14 Beecham Group Plc Chemical compounds
JP2751385B2 (ja) 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
US5440505A (en) * 1994-01-21 1995-08-08 Intel Corporation Method and circuitry for storing discrete amounts of charge in a single memory element
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5756473A (en) 1995-11-21 1998-05-26 Abbott Laboratories 6-O-methyl erythromycin D and process for making
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5808017A (en) 1996-04-10 1998-09-15 Abbott Laboratories Process for preparing erythromycin A oxime
US5844105A (en) * 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
PT915899E (pt) * 1996-07-29 2004-11-30 Abbott Lab Preparacao da forma cristalina ii da eritromicina
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US5864023A (en) 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
US5852180A (en) 1997-11-17 1998-12-22 Abbott Laboratories Chemical synthesis of 6-O-alkyl erythromycin A
US5932710A (en) 1997-12-01 1999-08-03 Abbott Laboratories Process for preparing 6-O-alkyl-9-oxime erythromycin B
US5892008A (en) 1997-12-16 1999-04-06 Abbott Laboratories Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives
KR100377159B1 (ko) 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
PT1254146E (pt) * 1999-12-16 2005-10-31 Teva Pharma Processos de preparacao de polimeros de claritromicina e novo polimorfo iv
PL356645A1 (en) * 2000-01-11 2004-06-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
AU2578701A (en) 2000-02-29 2001-09-12 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
HUP0204252A2 (hu) 2003-03-28
RU2002118308A (ru) 2004-02-20
AU2001222619C1 (en) 2006-01-12
IS6463A (is) 2002-07-09
EP1280535B1 (de) 2005-02-09
EP1280535A4 (de) 2003-02-05
AU2001222619B8 (en) 2005-07-14
WO2001051059A1 (en) 2001-07-19
AU2261901A (en) 2001-07-24
HRP20020572A2 (en) 2005-04-30
DE60018119D1 (de) 2005-03-17
EP1280535A1 (de) 2003-02-05
US20020028920A1 (en) 2002-03-07
CA2397092A1 (en) 2001-07-19
SI1280535T1 (de) 2005-08-31
US6987175B2 (en) 2006-01-17
JP2003519661A (ja) 2003-06-24
AU2001222619B2 (en) 2005-04-28
CN1450903A (zh) 2003-10-22
KR20020071012A (ko) 2002-09-11
BR0016992A (pt) 2002-12-31
IL150698A0 (en) 2003-02-12
US6624292B2 (en) 2003-09-23
PT1280535E (pt) 2005-04-29
HUP0204252A3 (en) 2003-04-28
PL356645A1 (en) 2004-06-28
ES2236023T3 (es) 2005-07-16
US20030216555A1 (en) 2003-11-20
DE60018119T2 (de) 2006-05-04
DK1280535T3 (da) 2005-04-04
ZA200205229B (en) 2003-06-30

Similar Documents

Publication Publication Date Title
DE60018119D1 (de) Verfahren zur herstellung von polymorphen des clarithromycins
DE60134590D1 (de) Verfahren zur Herstellung von kohlensäurehaltigem Wasser
DE60228961D1 (de) Verfahren zur herstellung von l-aminosäuren durch enterobacteriaceae-stämmen mit verstärkter expression des mop-b
DE60130372D1 (de) Tauchformen, zusammensetzung für das tauchformen und verfahren zur herstellung von tauchformen
ATE302786T1 (de) Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv
ATE453648T1 (de) Verfahren zur herstellung von hexahydrofuroc2,3- büfuran-3-ol
ATE281447T1 (de) Verfahren zur herstellung von citalopram
AT7110U9 (de) Verfahren zur herstellung von amlodipinmaleat
DE50102118D1 (de) Verfahren zur herstelling von 1,2-dichlorethan
ATE328885T1 (de) Verfahren zur herstellung von sulfonamid- substituierten imidazotriazinonen
ATE506351T1 (de) Verfahren zur herstellung von 10,11-dihydro-10- oxo-5h-dibenzoäb,füazepin-5-carboxamid
DE50102444D1 (de) Verfahren zur herstellung von isocyanatoorganosilanen
ATE516267T1 (de) Vefahren zur herstellung von lactamen
ATE275149T1 (de) Verfahren zur herstellung von taxanderivaten
DE60134415D1 (de) Verfahren zur herstellung von wäscheweichmacherzusammensetzungen
DE50107372D1 (de) Verfahren zur herstellung von glasfliesen, glasbordüren, glasdekorpaneelen oder dgl.
DE60105991D1 (de) Verfahren zur herstellung von 6-aminocapronamid
DE60107061D1 (de) Verfahren zur herstellung von citalopram
DE50112449D1 (de) Verfahren zur herstellung von 3,3-diarylpropylaminen
ATE291569T1 (de) Verfahren zur herstellung von dnda
DE50103009D1 (de) Verfahren zur herstellung von 2-alkyl-3-chlorphenolen
ATE327995T1 (de) Verfahren zur herstellung von camptothectin
DE50002865D1 (de) Verfahren zur herstellung von benzofuranonoximen
ATE425143T1 (de) Verfahren zur herstellung von indolen
ATE387434T1 (de) Verfahren zur herstellung von mintlacton

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1280535

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
RZN Patent revoked